Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03816163
Brief Title: A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

First Submitted : January 23, 2019
First Submitted that Met QC Criteria : January 23, 2019
First Posted : January 25, 2019

Last Update Submitted that Met QC Criteria : March 21, 2019
Last Update Posted : March 25, 2019